z-logo
open-access-imgOpen Access
Cisplatin up‐regulates ICAM‐1 expression in endothelial cell via a NF‐κB dependent pathway
Author(s) -
Yu Minghua,
Han Jianqun,
Cui Peilin,
Dai Min,
Li Hongwei,
Zhang Jian,
Xiu Ruijuan
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2008.00696.x
Subject(s) - cisplatin , intercellular adhesion molecule 1 , umbilical vein , cell adhesion molecule , microbiology and biotechnology , intravital microscopy , cell adhesion , icam 1 , endothelium , biology , intracellular , immunology , in vitro , chemistry , cancer research , cell , biochemistry , in vivo , endocrinology , chemotherapy , genetics
The anticancer drug cis ‐diammindichloroplatin (cisplatin) can cause severe side‐effects, but to date, the mechanisms of action of these dangerous side‐effects have not been completely elucidated. Since cellular adhesion molecules (CAMs), by mediating the recruitment of circulating leukocytes to the blood vessel wall and their subsequent migration into the subendothelial spaces, play a crucial role in several pathophysiologic processes, we sought potential proof for CAMs in the pathophysiology of cisplatin‐induced vascular damage. In vitro , human umbilical vein endothelial cells (HUVECs) were subjected to various concentrations of cisplatin, considerable up‐regulation of intercellular adhesion molecule‐1 (ICAM‐1) but not P‐selectin, E‐selectin, and vascular cell adhesion molecule 1 at both messenger mRNA and protein expression levels were observed. Electrophoretic mobility shift assays and Western blotting analysis revealed that cisplatin up‐regulates ICAM‐1 expression in HUVECs via an NF‐kappaB‐dependent pathway. Further intravital microscopy study demonstrated that significantly higher ( P  < 0.01) numbers of rolling and sticking leukocytes on the wall of postcapillary venules in male Golden Syrian hamster's cheek pouch bearing a human cervical carcinoma were observed, while inhibition of ICAM‐1 by using specific anti‐ICAM‐1 antibody can attenuate cisplatin‐stimulated leukocyte/endothelium interactions. These data suggest that ICAM‐1 involves in the pathophsiologic process of cisplatin‐induced vascular toxicity and may be exploited for therapeutic advantage. ( Cancer Sci 2008; 99: 391–397)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here